{
    "clinical_study": {
        "@rank": "102599", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo 0% nitrite cream and placebo 0% citric acid cream"
            }, 
            {
                "arm_group_label": "Topical NO Dose A", 
                "arm_group_type": "Active Comparator", 
                "description": "3% sodium nitrite + 4.5% citric acid twice daily"
            }, 
            {
                "arm_group_label": "Topical NO Dose B", 
                "arm_group_type": "Active Comparator", 
                "description": "6% sodium nitrite + 9% citric acid once daily"
            }, 
            {
                "arm_group_label": "Topical NO Dose C", 
                "arm_group_type": "Active Comparator", 
                "description": "6% sodium nitrite + 9% citric acid twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Objective To assess the efficacy of the topical application of Nitric Oxide, delivered using\n      acidified nitrite.\n\n      Design Multicentre, randomized, controlled, dose ranging trial. A control arm and three\n      doses of acidified nitrite applied topically for 12 weeks with a further 12 weeks of follow\n      up.\n\n      Setting The trial setting was in European genitourinary medicine clinics\n\n      Participants Male and female volunteers over 18 years of age with between 2 and 50\n      ano-genital warts, 328 were screened for eligibility and 299 subjects from 40 centres were\n      randomised.\n\n      Exclusions Pregnancy; concomitant Sexually Transmitted Disease; internal warts requiring\n      treatment other than surgery /laser; diabetes ; Human Immunodeficiency Virus-positive,\n      immunosuppressed and/or using immunosuppressive therapies; drug abuse.\n\n      interventions compared\n\n        -  Control Placebo nitrite cream and placebo citric acid cream twice daily\n\n        -  A) 3% sodium nitrite + 4.5% citric acid creams twice daily\n\n        -  B) 6% sodium nitrite + 9% citric acid creams once daily\n\n        -  C) 6% sodium nitrite + 9% citric acid creams twice daily\n\n      Outcomes\n\n        -  Primary proportion of patients with complete clearance of target warts Secondary\n\n        -  Time to clearance\n\n        -  Wart area\n\n        -  Wart count\n\n        -  Patient and investigator assessment of efficacy\n\n        -  Safety\n\n        -  Tolerability\n\n        -  Adherence"
        }, 
        "brief_title": "A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts", 
        "completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Anogenital Warts", 
            "Condylomata Acuminata"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Condylomata Acuminata", 
                "Warts"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females over 18 years of age\n\n          -  2-50 warts in the anogenital region.\n\n          -  Female patients of child-bearing potential had to be willing to use a non-barrier\n             method of contraception at entry and for the duration of the study.\n\n          -  all patients had to be willing to use barrier protection for the duration of the\n             study.\n\n          -  All patients had to be able to comply with the requirements of the protocol and be\n             likely to return for follow-up visits and had to be contactable for the duration of\n             the study.\n\n        Exclusion Criteria:\n\n          -  Patients with clinically relevant abnormal haematology or biochemistry results\n             (determined from the sample taken at Visit 1).\n\n          -  Patients who had used an active therapy for anogenital warts within 2 weeks of\n             randomisation to study drug, i.e. Visit 2.\n\n          -  Patients who had used any local supportive medication, including topical\n             corticosteroids or beta-interferon, within 2 weeks of study entry.\n\n          -  Patients who had used medication known to adversely affect their haematology profile,\n             including local anaesthetics (benzocaine, lidocaine, etc), nitrofurantoin,\n             sulphonylureas and sulphonamides within 2 weeks of study entry.  [Word 'adversely'\n             added by Protocol Amendment 2, 7 May 2002.]\n\n          -  Patients with abnormal anogenital skin, such as eczema, or skin that had not healed\n             following surgery (cryosurgery, laser ablation or similar).\n\n          -  Patients who were known to have a concomitant sexually transmitted disease that\n             inhibited accurate assessment of their warts.\n\n          -  Patients who required treatment other than surgery or laser for internal warts.\n\n          -  Male patients with intra-urethral warts [deleted by Protocol Amendment 2, 7 May\n             2002].\n\n          -  Patients with diabetes (Type I or Type II diabetes).\n\n          -  Patients who were known to be HIV-positive.\n\n          -  Patients who were known to be immunosuppressed and/or using immunosuppressive\n             therapies.\n\n          -  Patients known to abuse alcohol and/or drugs or with a history of chronic alcohol or\n             drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "299", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015260", 
            "org_study_id": "ANA/2/C"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Topical NO Dose A", 
                    "Topical NO Dose B", 
                    "Topical NO Dose C"
                ], 
                "description": "Varying doses of sodium nitrite and citric acid co-applied to warts", 
                "intervention_name": "Topical NO", 
                "intervention_type": "Drug", 
                "other_name": "Acidified Nitrite vs Placebo"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo nitrite cream and placebo citric acid cream"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Citric Acid", 
                "Nitric Oxide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "human papilloma virus infection", 
            "Anogenital warts", 
            "condylomata acuminata"
        ], 
        "lastchanged_date": "December 12, 2013", 
        "number_of_arms": "4", 
        "official_title": "A Randomised, Multicentre, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy, Safety and Tolerability of Three Dose Regimens of Topical Nitric Oxide in Patients With Anogenital Warts", 
        "other_outcome": {
            "description": "Investigator assessment of staining (present or absent) at treatment site at Weeks 1, 2, 4, 6, 8, 10 and 12/withdrawal/early completion", 
            "measure": "Investigator assessment of staining", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "overall_official": {
            "affiliation": "Erasmus Medical Centre", 
            "last_name": "Willem I Van der Meijden", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of and area of target warts (up to 10 selected) at Baseline and Week 1, 2, 4, 6, 8, 10 and 12/withdrawal/early completion and at follow-up (Weeks 4, 8 and 12 after end of treatment)\nNumber of warts at Baseline (Week 0) and of remaining baseline warts at Week 1, 2, 4, 6, 8, 10 and 12/withdrawal/early completion and at Weeks 4, 8 and 12 of follow-up", 
            "measure": "Proportion of patients with complete clearance of target warts in Intention to treat (ITT) population", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total number of warts (baseline and new) at end of treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Patient assessment of efficacy (categorised as complete clearance, significant improvement, partial improvement, no change or worsening) at Week 12/withdrawal/early completion", 
                "measure": "Patient assessment of efficacy", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Investigator assessment of efficacy (categorised as complete clearance, significant improvement, partial improvement, no change or worsening) at Week 12/withdrawal/early completion", 
                "measure": "Investigator assessment of efficacy", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Patient assessment of itching, pain and burning (categorised as none, mild, moderate or severe) at treatment site at Screening and Weeks 1, 2, 4, 6, 8, 10 and 12/withdrawal/early completion", 
                "measure": "Patient assessment of tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12"
            }, 
            {
                "description": "Investigator assessment of erythema/eschar and oedema (using modified Draize scales from 0 to 4) at Baseline (Week 0), Weeks 1, 2, 4, 6, 8, 10 and 12/withdrawal/early completion and at follow-up (Weeks 4, 8 and 12 after end of treatment)", 
                "measure": "Investigator assessment of tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Adverse events throughout treatment period; unresolved events at end of treatment were followed up Heart rate and blood pressure at each visit during treatment Laboratory tests at Screening and Week 12/withdrawal/early completion Physical examination at Screening and at Week 12/withdrawal/early completion.", 
                "measure": "Safety of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks and followed up"
            }
        ], 
        "source": "University of Aberdeen", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Prostrakan Pharmaceuticals", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Erasmus Medical Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Aberdeen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}